GlobeNewsWire
30 Jul 2026, 02:27 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Regeneron's Phase 3 Fianlimab-Libtayo clinical trial failed to achieve statistical significance for its primary endpoint of progression-free survival in advanced melanoma patients. — The failure of a Phase 3 trial for a major drug candidate directly removes a potential future revenue stream and indicates a lack of efficacy for the treatment combination.
-0.80A securities class action lawsuit has been filed alleging Regeneron misled investors regarding the viability and prospects of the Fianlimab-Libtayo trial. — Lawsuits create legal uncertainty, potential financial liabilities, and reputational damage, though they are often secondary to the underlying clinical failure.
-0.40Regeneron modified the Phase 3 study in April 2026 to expand the number of patients eligible for analysis of progression-free survival. — Mid-study modifications often signal to investors that a trial is struggling to meet its original targets, which historically correlates with increased risk of failure.
-0.30Continue reading
6 related stories
Top 3 movers · tap to explore
Which stocks this story touches
The company is facing a securities class action lawsuit following the failure of a Phase 3 clinical trial and allegations of misleading investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
4h ago
